When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?-Reference-Cited by-同舟云学术

When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?

Published:2024-05 Issue: Volume:203 Page:107160
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Fu Chen,Tong Weiwei,Yu Lifeng,Miao Yuxi,Wei Qian,Yu Zhaojin,Chen Bo,Wei Minjie

Publisher

Elsevier BV

Reference162 articles.

1. Potential of antibody-drug conjugates (ADCs) for cancer therapy;Marei;Cancer Cell Int.,2022

2. Antibody drug conjugate: the "biological missile" for targeted cancer therapy;Fu;Signal Transduct. Target Ther.,2022

3. Immune stimulating antibody-photosensitizer conjugates via Fc-mediated dendritic cell phagocytosis and phototriggered immunogenic cell death for KRAS-mutated pancreatic cancer treatment;Kim;Small,2021

4. HER2-targeting TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR- dependent manner;Gonzalez;J. Immunother. Cancer,2019

5. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity;Ackerman;Nat. Cancer,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

2. HBsAg and TLR7/8 dual-targeting antibody-drug conjugates induce sustained anti-HBV activity in AAV/HBV mice: a preliminary study;Antibody Therapeutics;2024-07

3. Charge-guided masking of a membrane-destabilizing peptide enables efficient endosomal escape for targeted intracellular delivery of proteins;Acta Pharmaceutica Sinica B;2024-06